Novel Dual PPAR δ/γ Partial Agonist Induces Hepatic Lipid Accumulation through Direct Binding and Inhibition of AKT1 Phosphorylation, Mediating CD36 Upregulation-Reference-Cited by-同舟云学术

Novel Dual PPAR δ/γ Partial Agonist Induces Hepatic Lipid Accumulation through Direct Binding and Inhibition of AKT1 Phosphorylation, Mediating CD36 Upregulation

Published:2024-09-05 Issue: Volume: Page:
ISSN:0893-228X
Container-title:Chemical Research in Toxicology
language:en
Short-container-title:Chem. Res. Toxicol.

Author:

Cai Xiaotong¹,Zhang Qin¹,Wang Jiwei¹,Miao Yingying¹,Sun Yuqing¹,Xia Ziyin¹,Zhang Luyong¹²,Yu Qinwei¹,Jiang Zhenzhou¹³^ORCID

Affiliation:

1. New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China

2. Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China

3. Jiangsu Center for Pharmacodynamics Research and Evaluation, Key Laboratory of Drug Quality Control and Pharmacovigilance (Ministry of Education), China Pharmaceutical University, Nanjing 210009, China

Funder

China Postdoctoral Science Foundation

Natural Science Foundation of Jiangsu Province

National Natural Science Foundation of China

?Double First-Class? University project

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.chemrestox.4c00268

Reference38 articles.

1. The Global Epidemic of the Metabolic Syndrome

2. The prevalence and associated factors of metabolic syndrome in Chinese aging population

3. The Roles and Associated Mechanisms of Adipokines in Development of Metabolic Syndrome

4. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021

5. CRISPR-mediated BMP9 ablation promotes liver steatosis via the down-regulation of PPARα expression